Literature DB >> 15254790

Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.

F Blandini1, M Cosentino, A Mangiagalli, F Marino, A Samuele, E Rasini, R Fancellu, C Tassorelli, C Pacchetti, E Martignoni, G Riboldazzi, D Calandrella, S Lecchini, G Frigo, G Nappi.   

Abstract

In this study, we investigated whether changes in the regulatory mechanisms of apoptosis and oxidative stress may be detected, peripherally, in patients with Parkinson's disease (PD). For this purpose, we measured caspase-3 activity, Bcl-2 concentrations, peripheral benzodiazepine receptor (PBR) expression and Cu/Zn superoxide dismutase (SOD) concentrations in lymphocytes of untreated PD patients, patients treated only with L-Dopa or with L-Dopa and dopamine agonists and healthy volunteers. Caspase-3 activity was significantly increased in all PD patient groups. Patients treated with L-Dopa and dopamine agonists showed the lowest values of Bcl-2, coupled with the highest density of PBRs, while increased levels of Cu/Zn SOD were found in the group under monotherapy with L-Dopa. We also found, in PD patients, clear, negative correlations between Bcl-2 levels and both duration and severity of the disease. Our findings point to the existence of changes in the regulatory mechanisms of apoptosis in PD patients -- observable outside the central nervous system -- which seem to be modulated by the pharmacological treatment with dopaminergic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254790     DOI: 10.1007/s00702-004-0123-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  9 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 2.  Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2020-01-28       Impact factor: 3.575

3.  Wuzi Yanzong pill attenuates MPTP-induced Parkinson's Disease via PI3K/Akt signaling pathway.

Authors:  Wei Hang; Hui-Jie Fan; Yan-Rong Li; Qi Xiao; Lu Jia; Li-Juan Song; Yao Gao; Xiao-Ming Jin; Bao-Guo Xiao; Jie-Zhong Yu; Cun-Gen Ma; Zhi Chai
Journal:  Metab Brain Dis       Date:  2022-04-30       Impact factor: 3.584

4.  Chronic low-dose oxidative stress induces caspase-3-dependent PKCdelta proteolytic activation and apoptosis in a cell culture model of dopaminergic neurodegeneration.

Authors:  Martha Carvour; Chunjuan Song; Siddharth Kaul; Vellareddy Anantharam; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy.

Authors:  Francesca R Buttarelli; Annapia Circella; Clelia Pellicano; Dorina Tiple; Morena Giovannelli; Carlo Colosimo; Francesco E Pontieri
Journal:  J Neural Transm (Vienna)       Date:  2008-12-17       Impact factor: 3.575

6.  Abnormal serum concentrations of proteins in Parkinson's disease.

Authors:  Ira L Goldknopf; Jennifer K Bryson; Irina Strelets; Silvia Quintero; Essam A Sheta; Miguel Mosqueda; Helen R Park; Stanley H Appel; Holly Shill; Marwan Sabbagh; Bruce Chase; Eric Kaldjian; Katerina Markopoulou
Journal:  Biochem Biophys Res Commun       Date:  2009-08-31       Impact factor: 3.575

7.  Molecular Effects of L-dopa Therapy in Parkinson's Disease.

Authors:  Jolanta Dorszewska; Michal Prendecki; Margarita Lianeri; Wojciech Kozubski
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

8.  Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis.

Authors:  Kevin Peikert; Enrica Federti; Andreas Hermann; Lucia De Franceschi; Alessandro Matte; Gabriela Constantin; Enrica Caterina Pietronigro; Paolo Francesco Fabene; Paola Defilippi; Emilia Turco; Federico Del Gallo; Pietro Pucci; Angela Amoresano; Anna Illiano; Flora Cozzolino; Maria Monti; Francesca Garello; Enzo Terreno; Seth Leo Alper; Hannes Glaß; Lisann Pelzl; Katja Akgün; Tjalf Ziemssen; Rainer Ordemann; Florian Lang; Anna Maria Brunati; Elena Tibaldi; Immacolata Andolfo; Achille Iolascon; Giuseppe Bertini; Mario Buffelli; Carlo Zancanaro; Erika Lorenzetto; Angela Siciliano; Massimiliano Bonifacio; Adrian Danek; Ruth Helen Walker
Journal:  Acta Neuropathol Commun       Date:  2021-05-03       Impact factor: 7.801

Review 9.  Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.